Curative Effect of Entecavir Plus Thymosin for Patients with Hepatitis B Cirrhosis

Objective: To investigate the clinical effect of entecavir plus thymosin for patients with hepatitis B cirrhosis,and provide experience for the clinical treatment of the disease. Method: A total of 68 patients with hepatitis B cirrhosis from April 2010 to February 2013 in our hospital,were divided into the observation group and the control group randomly,34 patients in each group. The observation group were given the treatment of entecavir plus thymosin and the control group were given the treatment of entecavir on the basis of conventional symptomatic treatment. Before and after treatment,the liver function and four indexes of hepatic fibrosis of two groups were recorded and compared. Result: Before treatment,the liver function and four indexes of hepatic fibrosis of two groups had no statistical significance( P 0.05).After treatment,the TB and ALT of the observation group were lower than the control group( P 0.05),and the ALB value was higher than the control group( P 0.05). Four indexes of hepatic fibrosis of the observation group was lower than the control group,and the difference had statistical significance( P 0.05). Conclusion: The clinical effect of entecavir plus thymosin on improving the liver function of patients with hepatitis B cirrhosis is effective,has the strong antiviral ability,and achieve satisfactory clinical efficacy.